Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunology

SIGLEC9 tips the myeloid balance in glioblastoma

Nature Cancer volume 4, pages 1217–1219 (2023)Cite this article

Subjects

Glioblastoma is an aggressive brain tumor with a highly immunosuppressive environment that responds poorly to immune checkpoint inhibitors. A study shows that SIGLEC9+ monocyte-derived macrophages are enriched in glioblastomas that do not respond to immune checkpoint inhibitors, and targeting this receptor synergizes with immunotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: SIGLEC9+ monocyte-derived macrophages promote an immunosuppressive tumor microenvironment.

References

  1. Mei, Y. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00598-9 (2023).

    Article  PubMed  Google Scholar 

  2. Neftel, C. et al. Cell 178, 835–849.e821 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hara, T. et al. Cancer Cell 39, 779–792.e711 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Garofano, L. et al. Nat. Cancer 2, 141–156 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wischnewski, V. et al. Nat. Cancer 4, 908–924 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mehta, A. K. et al. Nat. Cancer 2, 66–82 (2021).

    Article  CAS  PubMed  Google Scholar 

  7. Mehta, A. K., Kadel, S., Townsend, M. G., Oliwa, M. & Guerriero, J. L. Front. Immunol. 12, 643771 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Casanova-Acebes, M. et al. Nature 595, 578–584 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Akkari, L. et al. Sci. Transl. Med. 12, eaaw7843 (2020).

    Article  CAS  PubMed  Google Scholar 

  10. Pombo Antunes, A. R. et al. Nat. Neurosci. 24, 595–610 (2021).

    Article  CAS  PubMed  Google Scholar 

  11. Chen, A. X. et al. Genome Med. 13, 88 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lee, A. H. et al. Nat. Commun. 12, 6938 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Zhang, J. Q., Biedermann, B., Nitschke, L. & Crocker, P. R. Eur. J. Immunol. 34, 1175–1184 (2004).

    Article  CAS  PubMed  Google Scholar 

  14. Ibarlucea-Benitez, I., Weitzenfeld, P., Smith, P. & Ravetch, J. V. Proc. Natl Acad. Sci. 118, e2107424118 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Magen, A. et al. Nat. Med. 29, 1389–1399 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Department of Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Thomas U. Marron

  2. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Thomas U. Marron

  3. Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Thomas U. Marron

  4. Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA

    Jennifer L. Guerriero

  5. Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA

    Jennifer L. Guerriero

Authors
  1. Thomas U. Marron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer L. Guerriero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer L. Guerriero.

Ethics declarations

Competing interests

T.U.M. has previously served on advisory and/or data safety monitoring boards for Rockefeller University, Regeneron, AbbVie, Merck, Bristol-Myers Squibb, Boehringer Ingelheim, Atara, AstraZeneca, Genentech, Celldex, Chimeric, DrenBio, Glenmark, Simcere, Surface, G1 Therapeutics, NGMbio, DBV Technologies, Arcus and Astellas, and has research grants from Regeneron, Bristol-Myers Squibb, Merck and Boehringer Ingelheim. J.L.G. serves or has previously served on advisory boards and/or as a scientific advisory board member for Array BioPharma/Pfizer, AstraZeneca, BD Biosciences, Carisma, Codagenix, Duke Street Bio, GlaxoSmithKline, Kowa, Kymera, OncoOne and Verseau Therapeutics, and has research grants from Array BioPharma/Pfizer, Duke Street Bio, Eli Lilly, GlaxoSmithKline and Merck.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marron, T.U., Guerriero, J.L. SIGLEC9 tips the myeloid balance in glioblastoma. Nat Cancer 4, 1217–1219 (2023). https://doi.org/10.1038/s43018-023-00603-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00603-1

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer